Wednesday, 8 April 2009

Sevelamer Carbonate (Renvela) 800 mg tablets: Impax Confirms Patent Challenge

Impax Lab announced (in a press release Here ) that it has initiated a challenge of the patents listed by Genzyme Corporation in connection with its Renvela® (sevelamer carbonate) 800 mg tablets.
Earlier, innovator sued generic companies like Impax (as reported by us Here) and Lupin (as reported by us Here) for filing ANDA for Sevelamer Hydrochloride.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker